Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease and Transplantation, Liver Disease Diagnosis and Treatment, Hepatitis C virus research, and Liver Diseases and Immunity.
GDF-15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes.
Impact of pharmacological sGC stimulation with Riociguat in experimental models of liver disease regression.
Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D.
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver disease.
Sex does not impact the performance of non-invasive tests for clinically significant portal hypertension in cACLD.
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
Inflammation remains a dynamic component of portal hypertension in regressive alcohol-related cirrhosis.
Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis.
Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models.
Impact of Underlying Portal Hypertension on Severity and Course of Acute-On-Chronic Liver Failure.
Pancreatic involvement and its prognostic impact in acute-on-chronic liver failure.
FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence.
Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension.
Clinical course of congestive hepatopathy pre/post heart transplantation.
Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist.
Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.
Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis.
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV).
Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response.
Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease.
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome.
Platelet Function Decreases with Increasing Severity of Liver Cirrhosis and Portal Hypertension-A Prospective Study.
Diabetes impairs the haemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation.
Young gastroenterologists angle: Friends of the UEG young talent group consensus statement on the structure of young gastroenterology sections.
Bacterial growth and ceftriaxone activity in individual ascitic fluids in an <i>in vitro</i> model of spontaneous bacterial peritonitis.
Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates.
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
Non-invasive tests for clinically significant portal hypertension after HCV cure.